Navigation Links
FDA Announces Voluntary Withdrawal of Pergolide Products

The U.S. Food and Drug Administration (FDA) today announced that manufacturers of pergolide drug products, which are used to treat Parkinson’s disease, will voluntarily remove// these drugs from the market because of the risk of serious damage to patients’ heart valves.

The products being withdrawn are Permax, the trade name for pergolide marketed by Valeant Pharmaceuticals, and two generic versions of pergolide manufactured by Par and Teva. Pergolide is in a class of medications called dopamine agonists and is used with levodopa and carbidopa to manage the symptoms (tremors and slowness of movement) of Parkinson’s disease.

In 2006, an estimated 12,000 patients received prescriptions for pergolide from retail pharmacies in the United States. Patients taking pergolide should contact their doctors to discuss alternate treatments. Patients should not stop taking the medication, as stopping pergolide abruptly can be dangerous.

There are alternative therapies available for Parkinson’s disease, including three other dopamine agonists that have not been associated with valvular heart disease. The removal of pergolide products is not expected to adversely affect patient care because of the alternative therapies available.

“Based on important new drug safety information, FDA has been working with the manufacturers of pergolide products to voluntarily remove these drugs from the market,” said Douglas Throckmorton, M.D., deputy director of FDA’s Center for Drug Evaluation and Research. “The FDA’s increased evaluation of post-market safety is benefiting the public because, in this case, as new data about the product became available, we were able to remove a less safe drug from the market.”

Two recent New England Journal of Medicine studies confirm previous findings associating pergolide with increased chance of regurgitation (backflow of blood) of the mitral, tricuspid, and aortic valves of the heart. Valve regurgitat
'"/>




Page: 1 2

Related medicine news :

1. Ramdoss Announces Introduction of RCH-II
2. Britain Announces Third Transfusion Related Mad Cow Case
3. Tibet Announces the Dalai Lama’s Tour of South Americ
4. Indian PM Announces Of Setting Up India Study Center At Tashkent
5. PowderMed Announces Needle-Less Flu Vaccine
6. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
7. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
8. Australian Government Announces Survey To Tackle Childhood Obesity
9. New Zealand Announces 10-year Plan For Betterment Of Mental Health Care
10. Apollo Announces Research on Indian Cardiac Epidemic
11. Government Announces Steps To Promote Ayurvedic Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: FDA Announces Voluntary Withdrawal Pergolide Products

(Date:8/20/2014)... August 20, 2014 Biocide Systems ... on Wrench Advisors as a consultant and partner ... large accounts. , As Wrench Advisors explains on ... help your organization plan and execute programs by ... distribution channels. Our experience developing joint venture partnerships ...
(Date:8/20/2014)... TX (PRWEB) August 20, 2014 The ... Surgery (ACPS), has expanded its presence throughout Houston to ... Mann Eye Institute and Laser Center building. ACPS plastic ... natural step forward for ACPS, which has risen to ... plastic surgery practices in the state since its establishment ...
(Date:8/20/2014)... Aug. 20, 2014 (HealthDay News) -- White, straight women ... than minority, bisexual or lesbian women, a new study ... American women, aged 21 to 44, who took part ... of the National Survey of Family Growth study. ... women said they sought treatment for infertility. This ranged ...
(Date:8/20/2014)... receiving mental health services from the Veterans Health Administration ... among all areas studied. , The RAND Corporation study, ... a substance use disorder were less satisfied than other ... abuse problems also were less likely than others to ... decisions. , The findings, published in the journal ...
(Date:8/20/2014)... predict both breast cancer relapses and responses to ... The newly found marker could help doctors classify ... regimen that is more effective. The discovery was ... of Molecular and Cell Biology (IMCB), and the ... the National University of Singapore (NUS). , Despite ...
Breaking Medicine News(10 mins):Health News:Biocide Systems Announces Partnership with Wrench Advisors 2Health News:Aesthetic Center for Plastic Surgery Expands Its Reach in Texas 2Health News:White Women More Likely to Seek Fertility Treatment: Report 2Health News:Survey finds veterans generally satisfied with mental health care 2Health News:Novel gene predicts both breast cancer relapse and response to chemotherapy 2
... of winning a battle with cancer, as opposed to adults, ... years ago.// A recent report has explained that despite ... absolve them from the risks of long-term health problems in ... Childhood Cancer Survivor Study is a long-standing pioneer in the ...
... patients with severe psoriasis, appear to be at increased ... in the October 11 issue of JAMA.// ,Psoriasis ... percent to 3 percent of the adult population. It ... increased C-reactive protein levels, which have been linked to ...
... Kankova and colleagues from the Departments of Parasitology, Microbiology ... and GynCentrum, in the Czech Republic, women with dormant ... who are Toxoplasma negative. // ,Toxoplasma gondii ... with a universal occurrence of 20-80%. This study is ...
... for answers, but when it comes to cancer, physicians ... cancers. While certain tests can indicate the possibility of ... to monitor patients for cancer currently is not available ... University of Virginia School of Medicine are out to ...
... Parents with allergic symptoms like wheezing, asthma, hay ... to their infants too, according to a study by ... practice of avoiding skin testing for airborne allergens before ... in this high-risk group can be detected early and ...
... dengue death was reported in the capital, taking the toll ... city hospitals.// ,The total number of dengue cases in ... victim of the mosquito-borne viral disease was 25-year-old Farahan of ... Medical Science (AIIMS) here Friday and died in the early ...
Cached Medicine News:Health News:Childhood Cancer Survivors May Suffer Health Problems in Adulthood 2Health News:Psoriasis Associated With Increased Risk For Heart Attack 2Health News:Effect of parasitic infection on baby's sex 2Health News:Researchers Developing Office-Based Cancer Screening Test 2Health News:Allergy Sufferers Pass on Allergies to their Children 2Health News:Dengue Claims Yet Another Victim in Delhi 2
(Date:8/20/2014)... , Aug. 20, 2014   Ventana Medical ...  Group, today announced that its VENTANA System for ... in the European Union for routine pathology, including ... consisting of VENTANA Virtuoso software coupled with either ... HT slide scanner, provides automated digital slide creation, ...
(Date:8/20/2014)... Mass. , Aug. 20, 2014 /PRNewswire/ ... electrophysiology (EP) mapping and ablation device market ... use ablation to treat atrial fibrillation (AF). ... primary treatment option for AF will spur ... this application, such as advanced loop diagnostic ...
(Date:8/20/2014)... , Aug. 20, 2014  Amerigen Pharmaceuticals Ltd. ... Co. Ltd., has received Chinese FDA (CFDA) approval ... mg Tablets into the China ... marketing and distribution agreement with Sinochem Jiangsu Pharmaceutical ... its US FDA approved and China CFDA certified ...
Breaking Medicine Technology:Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 2Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 3Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 2Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 3Amerigen Pharmaceuticals Ltd. announces that its Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA (CFDA) approval and has subsequently launched its generic Mecobalamin 0.5 mg Tablets into the China domestic mark 2
... South Korea, Feb. 25 Dong-A PharmTech Co., ... Pharma, has initiated,a 200 patient, phase 2 proof ... udenafil, a long acting phosphodiesterase type 5 inhibitor, ... European,study is designed to investigate the safety and ...
... Enterprise Intelligence Systems to Healthcare Market, ... #1841 --,Harris Corporation (NYSE: HRS ), ... joined forces with Cancer Treatment,Services International (CTSI) ... oncology. Harris will provide advanced imaging and ...
Cached Medicine Technology:Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil 2Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil 3Harris Corporation Teams with Cancer Treatment Services International to Advance Oncology Treatment 2
Manual Lensmeter....
Lightweight, cordless lensmeter....
Lightweight, cordless lensmeter....
... 101 is well suited for measuring ... well as conventional spectacle lenses. It ... a full 90-degree inclination, which facilitates ... used in the vertical position. The ...
Medicine Products: